Back to News
Market Impact: 0.1
Vir Biotechnology, Inc. Appoints Suzanne Topalian, M.D., to Board of Directors
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
On October 26, 2026, Vir Biotechnology’s board approved expanding from eight to nine members and appointed Suzanne Topalian, M.D., to the newly created seat. She was appointed as a Class III director; the provided article text does not include further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- FedEx beats expectations, raises outlook in first report since calendar adjustment
- Warsh says politics played no role in Fed’s rate decision by group he is ’honored’ to lead
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Tencent’s Cloud Boss Plays Long Game to Patch ‘Leaky’ AI Ship
- Microsoft reveals strong cloud growth amid financial reporting overhaul
- ECB to hold rates as investors focus on French bonds, Lagarde’s future